LOS ANGELES--(BUSINESS WIRE)--CytRx Corporation (NASDAQ:CYTR), a biopharmaceutical company specializing in oncology, today reported financial results for the 12 months ended December 31, 2011, and provided a business update.
“We are on track to report important progress this year with our oncology clinical programs,” said President and Chief Executive Officer Steven A. Kriegsman. “With INNO-206, our tumor-targeting conjugate of the widely used chemotherapeutic agent doxorubicin, we are completing our Phase 1b/2 clinical trial in patients with solid tumors, primarily soft tissue sarcomas (STS), who have failed multiple treatments.
“We are on track to report important progress this year with our oncology clinical programs,” said President and Chief Executive Officer Steven A. Kriegsman. “With INNO-206, our tumor-targeting conjugate of the widely used chemotherapeutic agent doxorubicin, we are completing our Phase 1b/2 clinical trial in patients with solid tumors, primarily soft tissue sarcomas (STS), who have failed multiple treatments.
